Portefeuille d'ETF XBI (NYSE) - Page 3 | MetaTrader

Afficher le graphique complet Full chart

Aperçu Toutes les participations Heatmap

Principaux titres en portefeuille Market Value Shares Weight %

NBIX Neurocrine Biosciences Inc 88.32 M 622.68 K 1.13%

CRSP CRISPR Therapeutics AG 88.24 M 1.68 M 1.12%

ACAD ACADIA Pharmaceuticals Inc 88.22 M 3.30 M 1.12%

GRAL GRAIL Inc 87.37 M 1.02 M 1.11%

SMMT Summit Therapeutics Inc 83.85 M 4.79 M 1.07%

ARQT Arcutis Biotherapeutics Inc 83.24 M 2.87 M 1.06%

BEAM Beam Therapeutics Inc 81.67 M 2.95 M 1.04%

MLYS Mineralys Therapeutics Inc 77.33 M 2.13 M 0.99%

NUVL Nuvalent Inc 76.99 M 765.39 K 0.98%

DYN Dyne Therapeutics Inc 76.19 M 3.90 M 0.97%

KYMR Kymera Therapeutics Inc 76.02 M 977.05 K 0.97%

A

ACLX Arcellx Inc 75.50 M 1.16 M 0.96%

S

SLNO Soleno Therapeutics Inc 73.74 M 1.59 M 0.94%

CGON CG oncology Inc 72.96 M 1.76 M 0.93%

IDYA Ideaya Biosciences Inc 72.77 M 2.11 M 0.93%

VERA Vera Therapeutics Inc 72.41 M 1.43 M 0.92%

APLS Apellis Pharmaceuticals Inc 71.75 M 2.86 M 0.91%

SRPT Sarepta Therapeutics Inc 69.62 M 3.24 M 0.89%

COGT Cogent Biosciences Inc 65.74 M 1.85 M 0.84%

RXRX Recursion Pharmaceuticals Inc 65.66 M 16.05 M 0.84%

1
2
3
4
5
6
7
8

Nouvelles

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Jefferies abaisse la note de Tango Therapeutics en raison de la valorisation

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

La vente à découvert d’Intellia progresse le plus parmi les biotechs

What's The Dominant Trend In Earnings: AI Or Geopolitics?